Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,604.70
(
-0.30%
)
US TECH 100
23,594.40
(
-0.85%
)
Dow Jones
46,041.29
(
-0.40%
)
Brent Oil
104.32
(
-2.13%
)
Bitcoin
69,931.99
(
-1.84%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 168028

Friday, 10/25/2013 11:08:25 AM

Friday, October 25, 2013 11:08:25 AM

Post# of 257259
ABBV will report phase-3 top-line HCV data from some of the trials listed in #msg-92959364 this year data via press release(s); no further details available, but the first PR will presumably include SAPHIRE-1 and SAPHIRE-2.

ABBV’s 3Q13-results PR this morning said the HCV-data PR(s) would begin in 4Q13 (i.e. the current quarter); however, on today’s CC, ABBV’s CEO said the PR(s) would come in “late 2013,” which I interpret to mean after AASLD.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now